Android Apple

AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials

By Yahoo! Finance   |   1 month ago
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials

AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.